JAMES TULSKY received the Pathfinder in Palliative Care Award from the American Cancer Society.
DAVID MAURO was named as executive vice president and chief medical officer of Advaxis Inc.
RICHARD ZELLARS was named professor and chair of radiation oncology at the Indiana University School of Medicine, pending approval by the IU trustees. He will begin his new duties in January.
BENJAMIN NEEL was named director of the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center. He will begin Jan. 1, 2015.
BRAD POLLOCK was named chair of the Department of Public Health Sciences at the UC Davis School of Medicine.
The European Commission granted marketing approval for Imbruvica (ibrutinib) throughout the European Union, for relapsed or refractory mantle cell lymphoma, or chronic lymphocytic leukemia patients who have received at least one prior therapy, or in first line CLL patients in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemotherapy.
New members are elected by current active members through a selective process that recognizes individuals who have made major contributions to the advancement of the medical sciences, health care, and public health.
Celgene Corporation and Sutro Biopharma will collaborate on developing multispecific antibodies and antibody drug conjugates.
Priority Health announced it plans to cover the FoundationOne and FoundationOne Heme genomic profiles for patients with cancer developed by Foundation Medicine Inc.
The Centers for Medicare and Medicaid Services published two draft local coverage determinations for prostate cancer tests. The drafts were issued through Medicare contractor Palmetto GBA's MolDx Program.
